Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Developing a New Perfusate for Ex-Vivo Lung Perfusion

FY 2023-24

Summary
Lung transplantation (LTx) is the only curative intervention for patients with end-stage lung disease. Unfortunately, the success of LTx is limited by a shortage of donors and low utilization rates. Prior to transplantation, donor lung quality can be assessed via ex-vivo lung perfusion (EVLP). EVLP maintains physiological function of donor lungs outside of the body by providing mechanical ventilation and circulating perfusates. However, the most common perfusate, Steen solution, lacks adequate nutritional support and has yet to be optimized. Supplementing Steen solution with the constituent amino acids (glycine, cysteine, glutamine; GCQ) of glutathione, an important antioxidant, has been shown to improve cellular and cytoprotective functions. We therefore hypothesize that GCQ amino acids, with optimized ratios and concentrations, will better support metabolic demands and promote cytoprotective effects via antioxidants during EVLP to maintain basic cellular and physiological functions of lung cells. First, the effects of different GCQ formulas on basic cellular functions and cytoprotective mechanisms of human lung cells will be screened in a basic cell culture. Solutions that perform significantly better than controls will be further tested in an EVLP cell culture model to simulate EVLP stress. Finally, a porcine lung injury EVLP model will be facilitated with surgical staff and further mechanistic tests will be performed to validate the mechanisms of the best performing solutions in cell culture. The selected formula may be manufactured and used as a new clinical standard. Overall, an improved perfusate may provide the opportunity to increase the utilization rate and quality of donor lungs, which may address the donor shortage and improve patient outcomes. 
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
506192
Name
Rokoss Kate
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Developing a New Perfusate for Ex-Vivo Lung Perfusion
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Amino Acid; Antioxidant; Cell Culture; Cytoprotective; Ex-Vivo Lung Perfusion; Lung; Perfusate Solution; Porcine Animal Model; Pulmonary; Transplant
Abstract
Lung transplantation (LTx) is the only curative intervention for patients with end-stage lung disease. Unfortunately, the success of LTx is limited by a shortage of donors and low utilization rates. Prior to transplantation, donor lung quality can be assessed via ex-vivo lung perfusion (EVLP). EVLP maintains physiological function of donor lungs outside of the body by providing mechanical ventilation and circulating perfusates. However, the most common perfusate, Steen solution, lacks adequate nutritional support and has yet to be optimized. Supplementing Steen solution with the constituent amino acids (glycine, cysteine, glutamine; GCQ) of glutathione, an important antioxidant, has been shown to improve cellular and cytoprotective functions. We therefore hypothesize that GCQ amino acids, with optimized ratios and concentrations, will better support metabolic demands and promote cytoprotective effects via antioxidants during EVLP to maintain basic cellular and physiological functions of lung cells. First, the effects of different GCQ formulas on basic cellular functions and cytoprotective mechanisms of human lung cells will be screened in a basic cell culture. Solutions that perform significantly better than controls will be further tested in an EVLP cell culture model to simulate EVLP stress. Finally, a porcine lung injury EVLP model will be facilitated with surgical staff and further mechanistic tests will be performed to validate the mechanisms of the best performing solutions in cell culture. The selected formula may be manufactured and used as a new clinical standard. Overall, an improved perfusate may provide the opportunity to increase the utilization rate and quality of donor lungs, which may address the donor shortage and improve patient outcomes. 
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rokoss, Kate
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~